6,498 results match your criteria Journal of Alzheimer's Disease[Journal]


Treatment of Alzheimer's Disease: Trazodone, Sleep, Serotonin, Norepinephrine, and Future Directions.

J Alzheimers Dis 2019 ;67(3):923-930

War Related Illness and Injury Study Center, VA Palo Alto Health Care System and Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, CA, USA.

In this issue, an article by La et al. provides evidence that trazodone delayed cognitive decline in 25 participants with Alzheimer's disease (AD), mild cognitive impairment, or normal cognition. For participants considered to have AD pathology, trazodone non-users declined at a rate 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-181106DOI Listing
January 2019
1 Read

Effect of Navigation Problems, Assessment Location, and a Practice Test on Driving Assessment Performance for People with Alzheimer's Disease.

J Alzheimers Dis 2019 ;67(3):1035-1043

School of Health, Medical and Applied Sciences, Central Queensland University, Melbourne, VIC, Australia.

Background: People with Alzheimer's disease may be required to undertake clinical and on-road assessments to determine fitness to drive. The manner in which on-road assessments are conducted with drivers who do and do not have navigational problems may affect the outcome.

Objectives: Investigate the effect of 1) navigational difficulties, 2) location of assessment (un/familiar area) and assessment order, and 3) undertaking a second assessment (practice), on passing an on-road driving assessment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-181069DOI Listing
January 2019
1 Read

Is Alzheimer's Disease Risk Modifiable?

J Alzheimers Dis 2019 ;67(3):795-819

Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.

Population-based clinic-pathological studies have established that the most common pathological substrate of dementia in community-dwelling elderly people is mixed, especially Alzheimer's disease (AD) and cerebrovascular ischemic disease (CVID), rather than pure AD. While these could be just two frequent unrelated comorbidities in the elderly, epidemiological research has reinforced the idea that mid-life (age <65 years) vascular risk factors increase the risk of late-onset (age ≥ 65 years) dementia, and specifically AD. By contrast, healthy lifestyle choices such as leisure activities, physical exercise, and Mediterranean diet are considered protective against AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD181028DOI Listing
January 2019

The MemTrax Test Compared to the Montreal Cognitive Assessment Estimation of Mild Cognitive Impairment.

J Alzheimers Dis 2019 ;67(3):1045-1054

War Related Illness and Injury Study Center, VA Palo Alto HCS, Palo Alto, CA, USA.

Cognitive impairment is a leading cause of dysfunction in the elderly. When mild cognitive impairment (MCI) occurs in elderly, it is frequently a prodromal condition to dementia. The Montreal Cognitive Assessment (MoCA) is a commonly used tool to screen for MCI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-181003DOI Listing
January 2019

Small Molecule Amyloid-β Protein Precursor Processing Modulators Lower Amyloid-β Peptide Levels via cKit Signaling.

J Alzheimers Dis 2019 ;67(3):1089-1106

Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA.

Alzheimer's disease (AD) is characterized by the accumulation of neurotoxic amyloid-β (Aβ) peptides consisting of 39-43 amino acids, proteolytically derived fragments of the amyloid-β protein precursor (AβPP), and the accumulation of the hyperphosphorylated microtubule-associated protein tau. Inhibiting Aβ production may reduce neurodegeneration and cognitive dysfunction associated with AD. We have previously used an AβPP-firefly luciferase enzyme complementation assay to conduct a high throughput screen of a compound library for inhibitors of AβPP dimerization, and identified a compound that reduces Aβ levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180923DOI Listing
January 2019

p-Hydroxybenzyl Alcohol Prevents Memory Deficits by Increasing Neurotrophic Factors and Decreasing Inflammatory Factors in a Mice Model of Alzheimer's Disease.

J Alzheimers Dis 2019 ;67(3):1007-1019

Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo, Zhejiang, China.

p-hydroxybenzyl alcohol (HBA) is one of the major components of Gastrodia elata Blume (GEB) phenolic compound. HBA has been reported to have a protective effect on amyloid-β (Aβ) induced cell death. However, the systemic effects and the detail molecular mechanism of HBA in Alzheimer's disease (AD) animal models is not clear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180910DOI Listing
January 2019

Clinical Presentation, Diagnostic Features, and Mortality in Dementia with Lewy Bodies.

J Alzheimers Dis 2019 ;67(3):995-1005

Department of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK.

Background: Dementia with Lewy bodies (DLB) is the second most common degenerative dementia in older people. However, rates of misdiagnosis are high, and little is known of its natural history and outcomes. Very few previous studies have been able to access routine clinical information for large, unbiased DLB cohorts in order to establish initial presentation, neuropsychological profile, and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180877DOI Listing
January 2019

Connectivity Between Brain Networks Dynamically Reflects Cognitive Status of Parkinson's Disease: A Longitudinal Study.

J Alzheimers Dis 2019 ;67(3):971-984

Applied Neuroscience Research Group, Central European Institute of Technology, Masaryk University (CEITEC MU), Brno, Czech Republic.

Background: Cognitive impairment in Parkinson's disease (PD) is associated with altered connectivity of the resting state networks (RSNs). Longitudinal studies in well cognitively characterized PD subgroups are missing.

Objectives: To assess changes of the whole-brain connectivity and between-network connectivity (BNC) of large-scale functional networks related to cognition in well characterized PD patients using a longitudinal study design and various analytical methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180834DOI Listing
January 2019

Midlife Long-Hour Working and Later-life Social Engagement Are Associated with Reduced Risks of Mild Cognitive Impairment among Community-Living Singapore Elderly.

J Alzheimers Dis 2019 ;67(3):1067-1077

The Guangxi Colleges and Universities Key Laboratory of Prevention and Control of Highly Prevalent Diseases, School of Public Health, Guangxi Medical University, Nanning, Guangxi Province, China.

Mild cognitive impairment (MCI), as a transitional stage between normal aging and dementia, causes cognitive decline among one-fifth of elders aged 65 years and older. Health-related lifestyles (HRL) are generally regarded as modifiable influencing factors of cognitive decline. The present study investigated how HRLs at two different life stages (one at midlife and the other at later life) affect MCI occurrence among community-dwelling elders, as part of the Diet and Healthy Aging (DaHA) study in Singapore. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180605DOI Listing
January 2019

Factors Associated with Length of Stay in Hospital Patients with and Without Dementia.

J Alzheimers Dis 2019 ;67(3):1055-1065

Network Aging Research, University of Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany.

Background: Hospital care of older adults, especially of those with dementia, is associated with a high risk of complications and increased mortality. Adverse events are often triggered by hospital-related factors, hence the time spent in hospitals should be limited. There is little knowledge of the specific factors influencing hospitalizations of older persons. Read More

View Article

Download full-text PDF

Source
https://www.medra.org/servlet/aliasResolver?alias=iospress&a
Publisher Site
http://dx.doi.org/10.3233/JAD-180593DOI Listing
January 2019
1 Read

Resistance Exercise-Induced Responses in Physiological Factors Linked with Cognitive Health.

J Alzheimers Dis 2019 Feb 13. Epub 2019 Feb 13.

School of Psychology and Exercise Science, Murdoch University, Perth, Western Australia, Australia.

The global population is aging at an unprecedented rate giving rise to a greater prevalence of age-related illnesses such as dementia and vascular disease. Dementia affects approximately 47 million individuals globally with projections of 130 million by the year 2050. Late-onset Alzheimer's disease is the most common form of dementia, accounting for approximately 75% of all cases and is characterized by a progressive decline in cognitive function, memory, and cerebral volume. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-181079DOI Listing
February 2019

Cognitive Improvement with Glutathione Supplement in Alzheimer's Disease: A Way Forward.

J Alzheimers Dis 2019 Feb 13. Epub 2019 Feb 13.

Department of Clinical Engineering, Haukeland University Hospital, Bergen, Norway.

Alzheimer's disease (AD) is a devastating neurodegenerative disorder affecting millions of people worldwide. The actual cause of AD is still unknown. Oxidative stress is believed to be important player in AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-181054DOI Listing
February 2019

Identification of Key Long Non-Coding RNAs in the Pathology of Alzheimer's Disease and their Functions Based on Genome-Wide Associations Study, Microarray, and RNA-seq Data.

J Alzheimers Dis 2019 Feb 13. Epub 2019 Feb 13.

Innovative Drug Research and Bioinformatics Group, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.

The pathogenesis of Alzheimer's disease (AD) is identified to be significantly regulated by long non-coding RNA (lncRNA) based on in vivo and clinical experiments. Single nucleotide polymorphisms (SNPs) can strongly impact expression and function of lncRNA in AD, and previous genome-wide associations studies (GWAS) have discovered substantial amount of risk SNPs associated with AD. However, current studies omit the important information about SNPs when identifying potential AD-related lncRNAs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-181051DOI Listing
February 2019

Therapeutic Potential of AMP-Activated Protein Kinase in Alzheimer's Disease.

J Alzheimers Dis 2019 Feb 13. Epub 2019 Feb 13.

Department of Internal Medicine, Gerontology & Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Currently there is no cure or effective disease-modifying therapy for Alzheimer's disease (AD), the most common form of dementia that is becoming a global threat to public health. It is important to develop novel therapeutic strategies targeting AD pathophysiology particularly synaptic failure and cognitive impairments. Recent studies revealed several molecular signaling pathways potentially linked to brain pathology and synaptic failure in AD, including AMP-activated protein kinase (AMPK), a master kinase that plays a central role in the maintenance of cellular energy homeostasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-181043DOI Listing
February 2019

Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease.

J Alzheimers Dis 2019 Feb 13. Epub 2019 Feb 13.

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Mother-Child health (DINOGMI), University of Genoa, Italy.

Background: Several automatic tools have been implemented for semi-quantitative assessment of brain [18]F-FDG-PET.

Objective: We aimed to head-to-head compare the diagnostic performance among three statistical parametric mapping (SPM)-based approaches, another voxel-based tool (i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-181022DOI Listing
February 2019
1 Read

Endoplasmic Reticulum Stress in Tauopathies: Contrasting Human Brain Pathology with Cellular and Animal Models.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Laboratory of Amyloidosis and Neurodegeneration, Fundación Instituto Leloir, Buenos Aires, Argentina.

The accumulation and spreading of protein tau in the human brain are major features of neurodegenerative disorders known as tauopathies. In addition to several subcellular abnormalities, tau aggregation within neurons seems capable of triggering endoplasmic reticulum (ER) stress and the consequent unfolded protein response (UPR). In metazoans, full activation of a complex ER-UPR network may restore proteostasis and ER function or, if stress cannot be solved, commit cells to apoptosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-181021DOI Listing
February 2019

FTIR Spectroscopy of Cerebrospinal Fluid Reveals Variations in the Lipid: Protein Ratio at Different Stages of Alzheimer's Disease.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Faculty of Mathematics and Natural Sciences, Centre for Innovation and Transfer of Natural Sciences and Engineering Knowledge, University of Rzeszow, Poland.

Alzheimer's disease (AD) is a disease of advanced civilization and a common form of dementia in people over 65 years of age. We used Fourier transform infrared (FTIR) spectroscopy combined with principal component analysis (PCA) to determine changes in the quantity and quality of the cerebrospinal fluid from AD patients at three different stages of the disease (ADI, ADII, and ADIII), as well as from patients with mild cognitive impairment (MCI). Moreover, based on the FTIR spectra, we calculated the ratio of α-helix and β-sheet secondary protein structures as well as the lipid-protein balance as potential AD markers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-181008DOI Listing
February 2019
1 Read

A Potential Role for α-Amylase in Amyloid-β-Induced Astrocytic Glycogenolysis and Activation.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Department of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, Malmö, Sweden.

Background: Astrocytes produce and store the energy reserve glycogen. However, abnormal large glycogen units accumulate if the production or degradation of glycogen is disturbed, a finding often seen in patients with Alzheimer's disease (AD). We have shown increased activity of glycogen degrading α-amylase in AD patients and α-amylase positive glial cells adjacent to AD characteristic amyloid-β (Aβ) plaques. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180997DOI Listing
February 2019

Neuropathological Diagnoses of Demented Hispanic, Black, and Non-Hispanic White Decedents Seen at an Alzheimer's Disease Center.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Department of Neurology, University of California, Davis, Sacramento, CA, USA.

Our nation is becoming increasingly diverse; however, few autopsy studies examine multiple ethnoracial groups, especially Hispanics. We examined differences in neuropathological diagnoses of 435 deceased participants with dementia from three ethnoracial groups (35 Black, 28 Hispanic, and 360 non-Hispanic White) evaluated at the University of California Davis Alzheimer's Disease Center. We used novel applications of bootstrap resampling and logistic regression standardization to project neuropathological diagnostic rates for non-Hispanic Whites to minority sample characteristics to improve inference of findings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180992DOI Listing
February 2019

White Matter Hyperintensities in Alzheimer's Disease: A Lesion Probability Mapping Study.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Department of Neurology, Medical University of Graz, Graz, Austria.

Background/objective: Higher white matter hyperintensity (WMH) load has been reported in Alzheimer's disease (AD) patients in different brain regions when compared to controls. We aimed to assess possible differences of WMH spatial distribution between AD patients and age-matched controls by means of lesion probability maps.

Methods: The present study included MRI scans of 130 probable AD patients with a mean age of 73. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180982DOI Listing
February 2019
1 Read

Elevation of pS262-Tau and Demethylated PP2A in Retina Occurs Earlier than in Hippocampus During Hyperhomocysteinemia.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Key Laboratory of Ministry of Education of China for Neurological Disorders, Hubei Provincial Key Laboratory of Neurological Diseases, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China.

Hyperhomocysteinemia is an independent risk factor of Alzheimer's disease (AD), which is not diagnosed for many years before onset due to lack of peripherally detectable early biomarkers. Visual dysfunction is prevalent in AD patients and correlates with the severity of cognitive defects. Importantly, alterations in eyes can be non-invasively detected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180978DOI Listing
February 2019

Methionine Sulfoxide Reductase-B3 Risk Allele Implicated in Alzheimer's Disease Associates with Increased Odds for Brain Infarcts.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USA.

Genome-wide association studies identified a single nucleotide polymorphism (SNP) in the MSRB3 gene encoding Methionine Sulfoxide Reductase-B3 (MsrB3) to be associated with the risk for low hippocampal volume and late onset Alzheimer's disease (AD). Subsequently, we identified AD-associated abnormal patterns of neuronal and vascular MsrB3 expression in postmortem hippocampi. The present study investigated the relationship between the MSRB3 SNP rs61921502, G (minor/risk allele) and MRI measures of brain injury including total brain volume, hippocampal volume, and white matter hyperintensities using linear regression models; the presence of brain infarcts using logistic regression models; and the incidence of stroke, dementia, and AD using Cox proportional hazards models in 2,038 Framingham Heart Study Offspring participants with MRI administered close to examination cycle 7 (1998-2001). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180977DOI Listing
February 2019

The Influence of BDNF Val66Met Polymorphism on Cognition, Cerebrospinal Fluid, and Neuroimaging Markers in Non-Demented Elderly.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.

Background: The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism emerged as a risk factor for Alzheimer's disease (AD). However, little was known about its effects on the process of potential AD.

Objective: To explore the effects of the Val66Met polymorphism on cognition, cerebrospinal fluid (CSF), and neuroimaging markers in non-demented elderly individuals. Read More

View Article

Download full-text PDF

Source
https://www.medra.org/servlet/aliasResolver?alias=iospress&a
Publisher Site
http://dx.doi.org/10.3233/JAD-180971DOI Listing
February 2019
2 Reads

Vascular Burden Score Impacts Cognition Independent of Amyloid PET and MRI Measures of Alzheimer's Disease and Vascular Brain Injury.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

UC Davis Department of Neurology and Center for Neuroscience, Davis, CA, USA.

Background/objective: To determine the impact of vascular burden on rates of decline in episodic memory and executive function. We hypothesize that greater vascular burden will have an additive negative impact on cognition after accounting for baseline cognitive impairment, positron emission tomography (PET) amyloid burden, and magnetic resonance imaging (MRI) measures.

Methods: Individuals were followed an average of 5 years with serial cognitive assessments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180965DOI Listing
February 2019

The Association between Mushroom Consumption and Mild Cognitive Impairment: A Community-Based Cross-Sectional Study in Singapore.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

We examined the cross-sectional association between mushroom intake and mild cognitive impairment (MCI) using data from 663 participants aged 60 and above from the Diet and Healthy Aging (DaHA) study in Singapore. Compared with participants who consumed mushrooms less than once per week, participants who consumed mushrooms >2 portions per week had reduced odds of having MCI (odds ratio = 0.43, 95% CI 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180959DOI Listing
February 2019

Deep White Matter Lesions Are Associated with Early Recognition of Dementia in Alzheimer's Disease.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Department of Neurology, Gunma University Graduate School of Medicine, Maebashi, Japan.

Neuroimages of cerebral amyloid-β (Aβ) accumulation and small vessel disease (SVD) were examined in patients with various types of cognitive disorders using 11C-labeled Pittsburgh Compound B-positron emission tomography (PiB-PET) and magnetic resonance imaging (MRI). The mean cortical standardized uptake value ratio (mcSUVR) was applied for a quantitative analysis of PiB-PET data. The severity of white matter lesions (WML) and enlarged perivascular spaces (EPVS) on MRI were assessed to evaluate complicating cerebral SVD using semiquantitative scales. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180939DOI Listing
February 2019

The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus.

J Alzheimers Dis 2019 Feb 8. Epub 2019 Feb 8.

Department of Neurology, Brain Center Rudolph Magnus, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Background: Type 2 diabetes mellitus (T2DM) increases the risk of vascular cognitive impairment (VCI). It is unknown which type of vascular lesions and co-morbid etiologies, in particular Alzheimer's disease pathology, are associated with T2DM in patients with VCI, and how this relates to cognition and prognosis.

Objective: To compare brain MRI and cerebrospinal fluid (CSF) markers, cognition, and prognosis in patients with possible VCI with and without T2DM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180914DOI Listing
February 2019

Antiepileptic Drug Use Is Associated with an Increased Risk of Pneumonia Among Community-Dwelling Persons with Alzheimer's Disease-Matched Cohort Study.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

School of Pharmacy, University of Eastern Finland, Kuopio, Finland.

Background: Antiepileptic drugs (AEDs) have sedative properties which may lead to an increased risk of pneumonia.

Objectives: To investigate whether incident AED use is associated with an increased risk of pneumonia among community-dwelling persons with Alzheimer's disease (AD). In addition, we determined the risk according to duration of AED use and specific AEDs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180912DOI Listing
February 2019
1 Read

Early-Stage Alzheimer's Disease Is Associated with Simultaneous Systemic and Central Nervous System Dysregulation of Insulin-Linked Metabolic Pathways.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Department of Neurology, Rhode Island Hospital and the Alpert Medical School of Brown University, Providence, RI, USA.

Background: Brain insulin resistance is a well-recognized abnormality in Alzheimer's disease (AD) and the likely mediator of impaired glucose utilization that emerges early and progresses with disease severity. Moreover, the rates of mild cognitive impairment (MCI) or AD are significantly greater in people with diabetes mellitus or obesity.

Objective: This study was designed to determine whether systemic and central nervous system (CNS) insulin resistant disease states emerge together and thus may be integrally related. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180906DOI Listing
February 2019

Identification of a Simple and Novel Cut-Point Based Cerebrospinal Fluid and MRI Signature for Predicting Alzheimer's Disease Progression that Reinforces the 2018 NIA-AA Research Framework.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Champaign, IL, USA.

The 2018 NIA-AA research framework proposes a classification system with Amyloid-β deposition, pathologic Tau, and neurodegeneration (ATN) for diagnosis and staging of Alzheimer's disease (AD). Data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database can be utilized to identify diagnostic signatures for predicting AD progression, and to determine the utility of this NIA-AA research framework. Profiles of 320 peptides from baseline cerebrospinal fluid (CSF) samples of 287 normal, mild cognitive impairment (MCI), and AD subjects followed over a 3-10-year period were measured via multiple reaction monitoring mass spectrometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180905DOI Listing
February 2019

CD14 and Toll-Like Receptor 4 Promote Fibrillar Aβ42 Uptake by Microglia Through A Clathrin-Mediated Pathway.

J Alzheimers Dis 2019 Feb 9. Epub 2019 Feb 9.

Department of Neurology, School of Medicine, Sapporo Medical University, Sapporo, Japan.

We previously demonstrated that microglia play an essential role in clearance of amyloid-β (Aβ) in Alzheimer's disease (AD)-like pathology. Our prior work also showed that several receptors expressed on microglia participated in Aβ phagocytosis. However, clathrin-mediated endocytosis (CME), which is associated with production and release of Aβ in neurons, has received much less attention in the context of microglial Aβ uptake. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180904DOI Listing
February 2019

Distinctive Neurochemistry in Alzheimer's Disease via 7 T In Vivo Magnetic Resonance Spectroscopy.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Center for Magnetic Resonance Research and Department of Radiology, University of Minnesota, Minneapolis, MN, USA.

This study's objective was to increase understanding of biological mechanisms underlying clinical Alzheimer's disease (AD) by noninvasively measuring an expanded neurochemical profile and exploring how well this advanced technology distinguishes AD from cognitively normal controls. We measured concentrations of 14 neurochemicals using ultra-high field (7 T) ultra-short echo time (8 ms) magnetic resonance spectroscopy (MRS) in 16 participants with mild to moderate clinical AD and 33 age- and gender-matched control participants. MRS was localized to the posterior cingulate cortex (PCC), a region known to be impacted by AD, and the occipital cortex (OCC), a control region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180861DOI Listing
February 2019
1 Read

Psychosocial Intervention in Couples Coping with Dementia Led by a Psychotherapist and Social Worker: The DYADEM Trial.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Institute for Medical Sociology and Rehabilitation Science, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Background: Psychosocial interventions may improve the quality of life of both people with dementia (PWD) and their family caregivers. However, research is inconclusive and focused primarily on the quality of life of either the PWD or the caregiver, rather than on both.

Objective: Our aim was to evaluate the effect of couple-based interdisciplinary psychosocial intervention in patients with mild-to-moderate dementia on quality of life of both partners. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180812DOI Listing
February 2019

Cognitive Reserve in Midlife is not Associated with Amyloid-β Deposition in Late-Life.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

We examined associations between cognitive reserve and late-life amyloid-β deposition using florbetapir positron emission tomography (PET). We used data from the Atherosclerosis Risk in Communities (ARIC) and ARIC-PET Study. 330 dementia-free participants underwent PET scans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180785DOI Listing
February 2019

The Role of Apolipoprotein E Isoforms in Alzheimer's Disease.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Protein Design and Immunotherapy Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biociències, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.

Alzheimer's disease (AD), the most common type of dementia worldwide, is characterized by high levels of amyloid-β (Aβ) peptide and hyperphosphorylated tau protein. Genetically, the ɛ4 allele of apolipoprotein E (ApoE) has been established as the major risk factor for developing late-onset AD (LOAD), the most common form of the disease. Although the role ApoE plays in AD is still not completely understood, a differential role of its isoforms has long been known. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180740DOI Listing
February 2019

Impaired Glucose Tolerance and Reduced Plasma Insulin Precede Decreased AKT Phosphorylation and GLUT3 Translocation in the Hippocampus of Old 3xTg-AD Mice.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL, USA.

Several studies have demonstrated that mouse models of Alzheimer's disease (AD) can exhibit impaired peripheral glucose tolerance. Further, in the APP/PS1 mouse model, this is observed prior to the appearance of AD-related neuropathology (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180707DOI Listing
February 2019

Smart Home Technology: A New Approach for Performance Measurements of Activities of Daily Living and Prediction of Mild Cognitive Impairment in Older Adults.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Research Center of Institut universitaire de gériatrie de Montréal, Montreal, Canada.

Background: Functional assessment is of paramount importance when mild cognitive impairment is suspected, but common assessment tools such as questionnaires lack sensitivity. An alternative and innovative approach consists in using sensor technology in smart apartments during scenario-based assessments of instrumental activities of daily living (IADL). However, studies that investigate this approach are scarce and the technology used is not always transposable in healthcare settings. Read More

View Article

Download full-text PDF

Source
https://www.medra.org/servlet/aliasResolver?alias=iospress&a
Publisher Site
http://dx.doi.org/10.3233/JAD-180652DOI Listing
February 2019
1 Read

The Alz-tau Biomarker for Alzheimer's Disease: Study in a Caucasian Population.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Laboratory of Neuroscience, International Center for Biomedicine (ICC) and Faculty of Sciences, University of Chile, Santiago, Chile.

The establishment of a molecular biomarker for early detection of Alzheimer's disease (AD) is critical for diagnosis and follow up of patients, and as a quantitative parameter in the evaluation of potential new drugs to control AD. A list of blood biomarkers has been reported but none has been validated for the Alzheimer's clinic. The changes in hyperphosphorylated tau and amyloid peptide in the cerebrospinal fluid is currently used as a tool in the clinics and for research purposes, but this method is highly invasive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180637DOI Listing
February 2019

Air Pollution and Dementia: A Systematic Review.

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

University of New South Wales, Australia.

Background: Both air pollution and dementia are current and growing global issues. There are plausible links between exposure to specific air pollutants and dementia.

Objective: To systematically review the evidence base with respect to the relationship between air pollution and later cognitive decline and dementia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180631DOI Listing
February 2019

Modifiable Risk Factors Discriminate Memory Trajectories in Non-Demented Aging: Precision Factors and Targets for Promoting Healthier Brain Aging and Preventing Dementia?

J Alzheimers Dis 2019 Feb 11. Epub 2019 Feb 11.

Department of Psychology, University of Alberta, Edmonton, AB, Canada.

Background: Non-demented cognitive aging trajectories are characterized by vast level and slope differences and a spectrum of outcomes, including dementia.

Objective: The goal of AD risk management (and its corollary, promoting healthy brain aging) is aided by two converging objectives: 1) classifying dynamic distributions of non-demented cognitive trajectories, and 2) identifying modifiable risk-elevating and risk-reducing factors that discriminate stable or normal trajectory patterns from declining or pre-impairment patterns.

Method: Using latent class growth analysis we classified three episodic memory aging trajectories for n = 882 older adults (baseline Mage=71. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180571DOI Listing
February 2019

Serum Potassium Is Associated with Cognitive Decline in Patients with Lewy Body Dementia.

J Alzheimers Dis 2019 Feb 9. Epub 2019 Feb 9.

Department of Internal Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway.

Background: Epidemiological studies link serum potassium (K +) to cognitive performance, but whether cognitive prognosis in dementia is related to K + levels is unknown.

Objective: To determine if K + levels predict cognitive prognosis in dementia and if this varies according to diagnosis or neuropathological findings.

Methods: This longitudinal cohort study recruited 183 patients with mild Alzheimer's disease or Lewy body dementia (LBD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-181131DOI Listing
February 2019

On the Etiopathogenesis and Pathophysiology of Alzheimer's Disease: A Comprehensive Theoretical Review.

J Alzheimers Dis 2019 Feb 8. Epub 2019 Feb 8.

Johns Hopkins University.

Alzheimers' disease (AD) is the most common cause of dementia, with an estimated 5 million new cases occurring annually. Among the elderly, AD shortens life expectancy, results in disability, decreases quality of life, and ultimately, leads to institutionalization. Despite extensive research in the last few decades, its heterogeneous pathophysiology and etiopathogenesis have made it difficult to develop an effective treatment and prevention strategy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-181052DOI Listing
February 2019

Pharmacokinetics and Pharmacodynamics of LY2599666, a PEG-Linked Antigen Binding Fragment that Targets Soluble Monomer Amyloid-β.

J Alzheimers Dis 2019 Feb 7. Epub 2019 Feb 7.

Eli Lilly and Company, Indianapolis, IN, USA.

LY2599666 is a humanized, affinity-optimized monoclonal antibody antigen-binding fragment linked to a PEG molecule and targets soluble amyloid-β (Aβ) monomers. This first-in-human dose ascending study assessed pharmacokinetics (PK) (measured as serum free LY2599666 concentration) and pharmacodynamic (PD) effects (measured as plasma total soluble Aβ 40 and Aβ 42) after a single subcutaneous (SC) dose of 10, 25, 100, and 200 mg LY2599666 in healthy subjects. As LY2599666 binds to multiple soluble Aβ monomers, a two-target mediated drug disposition model (TMDD) was developed to simultaneously fit serum LY2599666 concentration and Aβ monomer levels. Read More

View Article

Download full-text PDF

Source
https://www.medra.org/servlet/aliasResolver?alias=iospress&a
Publisher Site
http://dx.doi.org/10.3233/JAD-180925DOI Listing
February 2019
1 Read

Present Algorithms and Future Treatments for Alzheimer's Disease.

J Alzheimers Dis 2019 Feb 7. Epub 2019 Feb 7.

Banner Alzheimer's Institute, Phoenix, AZ, USA.

An estimated 47 million people live with Alzheimer's disease (AD) and other forms of dementia worldwide. Although no disease-modifying treatments are currently available for AD, earlier diagnosis and proper management of the disease could have considerable impact on patient and caregiver quality of life and functioning. Drugs currently approved for AD treat the cognitive, behavioral, and functional symptoms of the disease and consist of three cholinesterase inhibitors (ChEIs) and the N-methyl-D-aspartate receptor antagonist memantine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180903DOI Listing
February 2019

Cerebral Amyloid-β Deposition Is Associated with Impaired Gait Speed and Lower Extremity Function.

J Alzheimers Dis 2019 Feb 7. Epub 2019 Feb 7.

Department of Physical Therapy, University of British Columbia (UBC), Vancouver, Canada.

Background: Impaired physical function (i.e., slowing of gait, muscle weakness, and poor mobility) is common in older adults with cognitive impairment and dementia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180848DOI Listing
February 2019
1 Read

Cerebrospinal Fluid Biomarkers in Idiopathic Normal Pressure Hydrocephalus versus Alzheimer's Disease and Subcortical Ischemic Vascular Disease: A Systematic Review.

J Alzheimers Dis 2019 Feb 7. Epub 2019 Feb 7.

Department of Neurology, Danish Dementia Research Centre, Rigshospitalet, University of Copenhagen, Copenhagen OE, Denmark.

Background: The diagnostic workup of idiopathic normal pressure hydrocephalus (iNPH) can be challenging due to an overlap in symptoms and neuroimaging features with other disorders. Despite a growing interest, a cerebrospinal fluid (CSF) biomarker profile in iNPH has not yet been identified.

Objective: To determine the CSF biomarkers with the greatest evidence for differentiating iNPH from the most common differential diagnoses, Alzheimer's disease (AD) and subcortical ischemic vascular disease (SIVD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180816DOI Listing
February 2019
1 Read

Subjective Cognitive Decline Below and Above the Age of 60: A Multivariate Study on Neuroimaging, Cognitive, Clinical, and Demographic Measures.

J Alzheimers Dis 2019 Feb 7. Epub 2019 Feb 7.

Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institutet, Stockholm, Sweden.

Subjective cognitive complaints in cognitively normal individuals are a relevant predictor of Alzheimer's disease (AD), cerebrovascular disease, and age-related tauopathy. Complaints starting after the age of 60 increase the likelihood of preclinical AD. However, this criterion is arbitrary and current data show that neurodegenerative disorders likely start before that age. Read More

View Article

Download full-text PDF

Source
https://www.medra.org/servlet/aliasResolver?alias=iospress&a
Publisher Site
http://dx.doi.org/10.3233/JAD-180720DOI Listing
February 2019
3 Reads
4.151 Impact Factor

Statistical Methodology for Multiclass Classifications: Applications to Dementia.

J Alzheimers Dis 2019 Feb 7. Epub 2019 Feb 7.

Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.

Alzheimer's disease (AD) is a common, devastating disease which carries a heavy economic burden. Accelerated efforts to identify presymptomatic stages of AD and biomarkers to classify the disease are urgent needs. Currently no biomarkers can perfectly discriminate individuals into multiple disease categories of AD (no cognitive impairment, mild cognitive impairment, and dementia). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-180580DOI Listing
February 2019
1 Read

Auditory Brainstem Dysfunction, Non-Invasive Biomarkers for Early Diagnosis and Monitoring of Alzheimer's Disease in Young Urban Residents Exposed to Air Pollution.

J Alzheimers Dis 2019 Feb 2. Epub 2019 Feb 2.

Department of Anatomy, Lake Erie College of Osteopathic Medicine, Erie, PA, USA.

Alzheimer's disease (AD) is a biological construct defined by abnormal deposits of hyperphosphorylated tau and amyloid-β. The 2050 projection for AD in the USA is 14 million. There is a strong association between AD, air pollution, and traffic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-181186DOI Listing
February 2019
2 Reads